Skip to main content
Concord Biotech Limited logo

Concord Biotech Limited — Investor Relations & Filings

Ticker · CONCORDBIO ISIN · INE338H01029 LEI · 335800FBIZZTLAXLXZ73 BSE.NS Manufacturing
Open in API
Filings indexed 225 across all filing types
Latest filing 2026-02-11 Board/Management Inform…
Country IN India
Listing BSE.NS CONCORDBIO

About Concord Biotech Limited

https://concordbiotech.com/

Concord Biotech Limited is a research and development-driven company specializing in the production of fermentation-based Active Pharmaceutical Ingredients (APIs) and finished formulations. The organization focuses on niche therapeutic areas, including immunosuppressants, oncology, anti-fungals, and anti-infectives. It maintains a significant global presence, supplying products to regulated markets such as the United States, Europe, and Japan. Concord Biotech operates large-scale fermentation facilities and is recognized for its expertise in complex manufacturing processes. Its operations are vertically integrated, covering the entire value chain from strain development and fermentation to downstream processing and formulation. The company adheres to international quality standards, holding certifications from major regulatory bodies like the USFDA and EUGMP, ensuring the delivery of high-quality pharmaceutical solutions to its global clientele.

Recent filings

Filing Released Lang Actions
General Updates
Board/Management Information Classification · 95% confidence The document is a formal disclosure letter addressed to stock exchanges regarding an update to the list of Key Managerial Personnel (KMPs) as per Regulation 30(5) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It does not contain financial statements, audit information, or detailed report content. The document is short (2428 characters) and serves as an announcement of a corporate governance update rather than a full report or detailed filing. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management.
2026-02-11 English
Change in Company Secretary/Compliance Officer
Interim / Quarterly Report Classification · 91% confidence The document is titled “Outcome of Board Meeting held today i.e. Wednesday, February 11, 2026 – Regulation 30…”, filed under SEBI Listing Regulations. It includes the full Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2025, along with the Limited Review Report, and key managerial personnel appointment details. The presence of actual interim financial statements, substantive financial data, and a limited review qualifies this as a comprehensive interim/quarterly report rather than just an earnings release or announcement. Therefore, this filing best fits the Interim / Quarterly Report category. 9M 2025
2026-02-11 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 90% confidence The document is a Regulation 30 Board meeting outcome announcement that includes the full unaudited standalone and consolidated financial results for the quarter and nine‐month period ended December 31, 2025, along with the statutory auditors’ limited review report. It contains substantive financial statements and actual numbers rather than mere highlights or links. This meets the definition of an Interim/Quarterly Report (IR) rather than a short earnings release or a mere publication notice. 9M 2025
2026-02-11 English
Spurt in Volume
Regulatory Filings Classification · 95% confidence The document is a letter from Concord Biotech Limited addressed to stock exchanges (BSE and NSE) regarding a clarification about a significant increase in trading volume of the company's security. It references a letter from NSE surveillance and states that there is no undisclosed or price sensitive information to be disclosed. The document is a regulatory communication responding to an inquiry from the stock exchange, not a financial report or detailed filing. It is short (2231 characters) and serves as a regulatory disclosure or clarification. It does not contain financial statements, management discussion, or other report content. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance communications that do not fit other categories.
2026-02-09 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is an invitation to an earnings call scheduled for discussing the unaudited standalone and consolidated financial results for the quarter and nine months ended 31 December 2025. It includes details about the call, participants, dial-in numbers, and contact information. There are no actual financial statements or detailed financial analysis included in the text. The document is essentially a notice or invitation to a conference call rather than the transcript or the financial report itself. Therefore, it fits the category of a Call Transcript (CT) only if it contained the full transcript, but since it is only an invitation, it does not qualify as a transcript. It is not an earnings release (ER) because it does not contain financial highlights or results, only an announcement of the call. Given the options, the best fit is Regulatory Filings (RNS) as a general regulatory announcement about the earnings call. Confidence is high because the document clearly states it is an earnings call invite and does not contain financial data or transcript.
2026-02-06 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a letter from Concord Biotech Limited addressed to stock exchanges (NSE and BSE) informing about an upcoming Board Meeting scheduled for February 11, 2026. The purpose of the meeting is to consider and approve the unaudited financial results for the third quarter and nine months ended December 31, 2025, along with the limited review report by statutory auditors. The letter also mentions the closure of the trading window in compliance with SEBI regulations. The document is short (2484 characters) and serves as a notification of a future event (board meeting and financial results announcement), not the financial results report itself. It does not contain actual financial data or detailed financial analysis. Therefore, it is an announcement related to a board meeting and financial results release, fitting best under Regulatory Filings (RNS) as a general regulatory announcement and compliance communication.
2026-02-06 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.